NCT03289962 — autogene cevumeran (BNT122) neoantigen vaccine trial
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Registry record
| Registry ID | NCT03289962 ↗ |
|---|---|
| Lead sponsor | Genentech, Inc. |
| Collaborators | BioNTech SE |
| Phase | Phase 1 |
| Status | Completed |
| Indication | Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers |
| Enrollment | 273 participants |
| Start date | 2017-12-21 |
| Primary completion | 2025-07-01 |
| Last registry update | 8 Jun 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03289962), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT03289962?
NCT03289962 (A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors) is registered on ClinicalTrials.gov as Phase 1, sponsored by Genentech, Inc..
Is NCT03289962 recruiting?
As of the 2026-06-08 registry update, NCT03289962 is listed as "Completed". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT03289962?
The lead sponsor is Genentech, Inc.. Collaborators: BioNTech SE.
What condition does NCT03289962 study?
The registered conditions are Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers. Primary completion is listed as 2025-07-01.
Are results available for NCT03289962?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03289962.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.